In accordance with a decision by the Board of Directors, Orion Corporation has on 2 March 2015 transferred altogether 141,949 Orion Corporation B-shares held by the company as a share reward for earning periods 2012-2014 and 2014 to the persons employed by the Orion Group and belonging to the Share-based Incentive Plans of the Orion Group. The transfer is based on the authorisation by the Annual General Meeting of 19 March 2013. The price per share of the transferred shares is EUR 28.9172, which is the volume weighted average quotation of the Orion Corporation B-share on 2 March 2015. Accordingly, the total transaction price of the transferred shares is EUR 4,104,767.62.
After the share transfer, the total number of own B-shares held by Orion Corporation is 427,716.
Orion Corporation has informed about the Share-based Incentive Plans in stock exchange releases on 18 February 2010 and 5 February 2013.
| Timo Lappalainen |
President and CEO
| Olli Huotari |
SVP, Corporate Functions
Orionintie 1A, FI-02200 Espoo, Finland
Orion is a globally operating Finnish company developing pharmaceuticals and diagnostic tests - a builder of well-being. Orion develops, manufactures and markets human and veterinary pharmaceuticals, active pharmaceutical ingredients and diagnostic tests. The company is continuously developing new drugs and treatment methods. The core therapy areas of Orion's pharmaceutical R&D are central nervous system (CNS) disorders, oncology and respiratory for which Orion developes inhaled Easyhaler® pulmonary drugs.
Orion's net sales in 2014 amounted to EUR 1,015 million and the company had about 3,500 employees. Orion's A and B shares are listed on NASDAQ Helsinki.